Review

Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations

Arie Gruzman, Gali Babai, Shlomo Sasson

Manuscript submitted April 10, 2009; resubmitted May 7, 2009; accepted May 9, 2009.

Keywords: diabetes, hyperglycemia, AMP, antihyperglycemic, drug target, energy metabolism, glucose transport, skeletal muscle, D-xylose

Abstract

In view of the epidemic nature of type 2 diabetes and the substantial rate of failure of current oral antidiabetic drugs the quest for new therapeutics is intensive. The adenosine monophosphate-activated protein kinase (AMPK) is an important regulatory protein for cellular energy balance and is considered a master switch of glucose and lipid metabolism in various organs, especially in skeletal muscle and liver. In skeletal muscles, AMPK stimulates glucose transport and fatty acid oxidation. In the liver, it augments fatty acid oxidation and decreases glucose output, cholesterol and triglyceride synthesis. These metabolic effects induced by AMPK are associated with lowering blood glucose levels in hyperglycemic individuals. Two classes of oral antihyperglycemic drugs (biguanidines and thiazolidinediones) have been shown to exert some of their therapeutic effects by directly or indirectly activating AMPK. However, side effects and an acquired resistance to these drugs emphasize the need for the development of novel and efficacious AMPK activators. We have recently discovered a new class of hydrophobic D-xylose derivatives that activates AMPK in skeletal muscles in a non insulin-dependent manner. One of these derivatives (2,4;3,5-dibenzylidene-D-xylose-diethyl-dithioacetal) stimulates the rate of hexose transport in skeletal muscle cells by increasing the abundance of glucose transporter-4 (GLUT-4) in the plasma membrane through activation of AMPK. This compound reduces blood glucose levels in diabetic mice and therefore offers a novel strategy of therapeutic intervention strategy in type 2 diabetes. The present review describes various classes of chemically-related compounds that activate AMPK by direct or indirect interactions and discusses their potential for candidate antihyperglycemic drug development.

Fulltext: HTML , PDF (453KB)

This article has been cited by other articles:

	Binding of cordycepin monophosphate to AMP-activated protein kinase and its effect on AMP-activated protein kinase activation Wang Z, Wang X, Qu K, Zhu P, Guo N, Zhang R, Abliz Z, Yu H, Zhu H Chem Biol Drug Des 2010. In press
	AMP-Activated protein kinase as a target for preconditioning in transplantation medicine Bouma HR, Ketelaar ME, Yard BA, Ploeg RJ, Henning RH Transplantation 2010. 90(4):353-358
	Curcumin protects hepatic stellate cells against leptin-induced activation in iitro by accumulating intracellular lipids Tang Y, Chen A Endocrinology 2010. Jul 21, epub ahead of print
	Does LKB1 Mediate Activation of Hepatic AMP-Protein Kinase (AMPK) and Sirtuin1 (SIRT1) After Roux-en-Y Gastric Bypass in Obese Rats? Peng Y, Rideout DA, Rakita SS, Gower WR Jr, You M, Murr MM J Gastrointest Surg 2010. 14(2):221-228
	Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells Kim T, Davis J, Zhang AJ, He X, Mathews ST Biochem Biophys Res Commun 2009. 388(2):377-382